The U.S. stock market opened with significant bullish momentum on Tuesday, March 31st, 2026, as investors reacted to a combination of cooling geopolitical tensions and a massive multi-billion dollar acquisition in the pharmaceutical sector. Following a period of heightened volatility, the "fear gauge" or VIX (^VIX) plummeted by nearly 10% to 27.57, signaling a renewed appetite for risk among market participants.
Market Indexes Opening Performance
Major market indexes showed broad-based strength in early trading. The tech-heavy NASDAQ (^IXIC) led the charge, surging 415.24 points, or 2.00%, to reach 21,209.88. This outperformance was mirrored by the S&P 500 (^GSPC), which climbed 1.56% to 6,442.45, comfortably crossing the 6,400 threshold. The Dow Jones Industrial Average (^DJI) also posted substantial gains, rising 599.64 points, or 1.33%, to 45,815.78.
Small-cap stocks outpaced their larger counterparts at the open, with the Russell 2000 (^RUT) jumping 2.07% to 2,464.03. In the commodities space, Gold Futures (GC=F) continued their historic run, gaining 1.60% to trade at $4,630.50 per ounce. Conversely, Crude Oil Futures (CL=F) stabilized at $102.48, down 0.39%, as reports suggested a potential de-escalation in Middle Eastern hostilities.
Upcoming Market Events and Economic Data
Investors are closely monitoring several key economic indicators released this morning. The Bureau of Labor Statistics reported the February Job Openings and Labor Turnover Survey (JOLTS) data at 10:00 AM ET, showing that job openings remained relatively stable at 6.9 million. However, the hires rate dipped to 3.1%, its lowest level since early 2020, suggesting a cooling in the labor market that may influence future Federal Reserve policy decisions.
Later today, the market will digest the latest Consumer Confidence index for March. Furthermore, the focus will shift to the retail sector after the closing bell, when Nike (NKE) is scheduled to release its third-quarter fiscal 2026 financial results. Analysts are looking for clues regarding the company’s turnaround strategy and its exposure to shifting consumer spending patterns amidst elevated energy costs.
Major Stock News and Corporate Developments
The standout story of the day is the definitive agreement for Biogen (BIIB) to acquire Apellis Pharmaceuticals (APLS) in a deal valued at approximately $5.6 billion. Under the terms of the agreement, Biogen will pay $41.00 per share in cash, representing a massive premium. Consequently, Apellis Pharmaceuticals (APLS) saw its stock price skyrocket by 136.4% to $40.40 in early trading. This acquisition is expected to bolster Biogen's portfolio in rare diseases and immunology, specifically with the addition of the drugs Empaveli and Syfovre.
The deal sent shockwaves through the healthcare sector, driving the Biotech ETF (XBI) up by 6.47%. Other biotech movers included Centessa Pharmaceuticals plc (CNTA), which rose 45.2%, and Apellis’ peer, PepGen Inc. (PEPG), which conversely fell 52.5% following a separate clinical update.
In the consumer space, McCormick & Company Incorporated (MKC) reported its Q1 2026 earnings before the open, meeting analyst expectations with an EPS of $0.61. Meanwhile, TD SYNNEX Corporation (SNX) and FactSet Research Systems Inc. (FDS) also released their quarterly results, contributing to the morning's active trading volume.
As the market heads into the afternoon, all eyes remain on the Federal Reserve's next moves and the impact of stabilizing oil prices on inflationary expectations. While the energy sector, represented by the Energy – Oil ETF (USO), lagged with a 1.60% decline, the broader market sentiment remains decidedly "risk-on" for the final trading day of the quarter.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.